Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P

被引：88

作者：

Koopman, Karen ^{[3
,6
]}

Le Bastard, Nathalie ^{[1
]}

Martin, Jean Jacques ^{[2
]}

Nagels, Guy ^{[3
,7
]}

De Deyn, Peter P. ^{[1
,2
,3
,5
]}

Engelborghs, Sebastiaan ^{[1
,3
,4
,5
]}

机构：

[1] Univ Antwerp, Lab Neurochem & Behav, Inst Born Bunge, Reference Ctr Biol Markers Memory Disorders, BE-2610 Antwerp, Belgium

[2] Univ Antwerp, Biobank, Inst Born Bunge, BE-2610 Antwerp, Belgium

[3] Middelheim Gen Hosp ZNA, Dept Neurol & Memory Clin, Antwerp, Belgium

[4] Univ Antwerp, Dept Nursing Sci, Fac Med, BE-2610 Antwerp, Belgium

[5] Univ Coll Antwerp, Dept Hlth Care Sci, Merksem, Belgium

[6] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands

[7] Natl Multiple Sclerosis Ctr, Melsbroek, Belgium

来源：

NEUROCHEMISTRY INTERNATIONAL | 2009年 / 55卷 / 04期

关键词：

Dementia; Alzheimer's disease; Cerebrospinal fluid; Biomarkers; Hyperphosphorylated tau; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; PHOSPHORYLATED-TAU; CLINICAL-DIAGNOSIS; BIOMARKERS; MARKERS; PERFORMANCE;

D O I：

10.1016/j.neuint.2009.02.017

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

To establish diagnostic accuracy (acc) and optimal cut-off levels of CSF tau phosphorylated at threonine 181 (P-tau(181P)) for discriminating Alzheimer's disease (AD) from non-AD dementias in autopsy-confirmed dementia patients, CSF levels of beta-amyloid peptide (A beta(1-42)). total tau protein (T-tau) and P-tau(181P) from patients with definite AD (n=95) and non-AD demential (n=50) were determined with single-parameter ELISA kits. Optimal P-tau(181P) cut-off levels for differentiating AD from pooled non-AD demential, dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) were 50.4 pg/mL (acc = 0.73), 52.8 pg/mL (acc = 0.73) and 35.3 pg/mL (acc = 0.90), respectively. The optimal CSF P-tau(181P) cut-off level for discriminating AD from non-AD demential was 50.4 pg/mL. Optimal CSF P-tau(181P) cut-off levels differed between non-AD diagnostic dementia categories. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：214 / 218

页数：5

共 27 条

[1]

Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109

[2] CSF biomarkers for mild cognitive impairment and early Alzheimer's disease [J].